Thermo Fisher Scientific, based mostly in Waltham, Mass., is shopping for gene and cell remedy producer Brammer Bio, situated in Cambridge, Mass. for $1.7 billion in money. Brammer Bio is a contract improvement and manufacturing group (CDMO) specializing in manufacturing viral vectors for gene and cell therapies. That is one thing of a sizzling space as of late as gene and cell therapies emerge out of analysis and into precise medical apply.
For instance, on Friday, March 22, bluebird bio, additionally headquartered in Cambridge, Mass., introduced it was opening its new gene remedy manufacturing facility in Durham, NC. That manufacturing unit will produce lentiviral vectors for its gene and cell therapies, together with bb2121 and bb21217 for a number of myelomas and probably LentiGLobin for transfusion-dependent beta-thalassemia (TDT) and sickle cell illness.
In line with a current industry report, there are virtually 300 gene therapies being developed to deal with greater than 100 ailments. Brammer has about 600 staffers at its major places in Massachusetts and Florida. The corporate was projected to usher in $250 million in income this yr.
“Brammer Bio shall be a thrilling addition to our pharma companies enterprise and can additionally strengthen Thermo Fisher’s management in serving pharma and biotech prospects,” acknowledged Marc N. Casper, president, and chief govt officer of Thermo Fisher Scientific. “Gene remedy is a space of accelerating focus for our prospects and is quick-evolving given its potential to deal with a spread of genetic issues.”
Casper went on to say, “The mixture of Brammer Bio’s viral vector capabilities with our GMP manufacturing experience and proprietary bioprocessing and cell tradition applied sciences uniquely positions us to companion with our prospects to drive the evolution of this extremely quick-rising market. The transaction is completely aligned with our Mission to allow our clients to make the world more healthy, cleaner and safer.”
Brammer is owned by its founders and Ampersand Capital Companions, the one institutional investor. Along with offering the medical and industrial vector for gene and cell remedy, it affords a course of an analytical improvement and regulatory assist. Brammer was based in 2016 by means of a merger of Brammer Biopharmaceuticals and Florida Biologix.
Matt is dealing with the biotechnology domain. He is a senior content material writer. He is a man with an awesome and charming persona. Aside from spending most of his time creating the articles most effectively, he likes to spend his leisure times in the cafeteria. Sipping his coffee and thinking about his subsequent articles.